Sign Out
Pregnancy: There are limited amount of data from the use of Betmiga in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Betmiga is not recommended during pregnancy and in women of childbearing potential not using contraception.
Breast-feeding: Mirabegron is excreted in the milk of rodents and therefore is predicted to be present in human milk (see Pharmacology: Toxicology: Preclinical safety data under Actions). No studies have been conducted to assess the impact of mirabegron on milk production in humans, its presence in human breast milk, or its effects on the breast-fed child.
Betmiga should not be administered during breast-feeding.
Fertility: There were no treatment-related effects of mirabegron on fertility in animals (see Pharmacology: Toxicology: Preclinical safety data under Actions). The effect of mirabegron on human fertility has not been established.
